Absci's ABS-201 anti-PRLR antibody trial begins with first healthy volunteers dosed.
ByAinvest
Thursday, Dec 4, 2025 8:08 am ET1min read
ABSI--
Absci Corporation has initiated a Phase 1/2a clinical trial to evaluate the safety and efficacy of ABS-201, an anti-prolactin receptor antibody. The trial aims to assess safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of the antibody. Interim data are expected in the second half of 2026. The trial design leverages operational synergies to enable accelerated registrational trials for androgenetic alopecia and a Phase 2 trial for endometriosis.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet